NSTM 最新10-Q变化
将 NSTM 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-15 与上一份 10-Q · 2025-11-12
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +19 | −23 | ~1 | 2 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~1 | 3 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)、法律诉讼、风险因素、其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-15
We are a development stage company and reported net losses of approximately $55,000 and $207,000 for the three months ended March 31, 2026 and 2025, respectively. We had current assets of approximately $101,000 and current liabilities of $2,048,000 as of March 31, 2026. As of December 31, 2025, our …
We have prepared our financial statements for the three months ended March 31, 2026, assuming that we will continue as a going concern. Our continuation as a going concern is dependent upon improving our profitability and the continuing financial support from our shareholders as well as Yissum’s abi…
The Company incurs general and administrative (“G&A”) expenses primarily related to professional fees, insurance and stock-based compensation. We incurred G&A expenses of approximately $5,000 and $95,000 for the three months ended March 31, 2026 and 2025, respectively. Specifically, professional fee…
Interest expense decreased by approximately $63,000 in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 primarily due to the settlement of the litigation funding agreement on May 9, 2025.
The Company has recorded no income tax expense as we have incurred operating losses and all deferred tax assets are fully offset by an income tax valuation allowance.
相对上期删除的文字 · 来源:10-Q · 2025-11-12
We are a development stage company and reported net income (losses) of approximately $2,469,000 and $(3,070,000) for the nine months ended September 30, 2025 and 2024, respectively, and $(77,000) and $(2,464,000), for the three months ended September 30, 2025 and 2024. We had current assets of appro…
We have prepared our financial statements for the nine months ended September 30, 2025 assuming that we will continue as a going concern. Our continuation as a going concern is dependent upon our ability to work with Yissum to monetize the former NewStem license agreement and intangible assets and t…
NewStem was a development stage Israeli biotech limited liability company focused on pioneering intellectual property related to haploid human embryonic stem cells for the development of personalized diagnostics and therapeutics for genetic and epigenetic diseases. NewStem incurred losses related to…
The Company incurs G&A expenses primarily related to professional fees, insurance and stock-based compensation. We incurred G&A expenses of approximately $198,000 and $894,000 for the nine months ended September 30, 2025 and 2024, respectively. Specifically, professional fees decreased by approximat…
We incurred G&A expenses of approximately $39,000 and $566,000 for the three months ended September 30, 2025 and 2024, respectively. Specifically, professional fees decreased by approximately $21,000 in the three months ended September 30, 2025 as compared to the three months ended September 30, 202…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议